No Data
William Blair Upgrades Kezar Life Sciences(KZR.US) to Buy Rating
William Blair Maintains Kezar Life Sciences(KZR.US) With Hold Rating
Express News | Kezar Life Sciences to Present at Virtual Kol Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update From the Palizade Trial for Lupus Nephritis on February 27, 2025
Express News | Kezar Life Sciences, Inc. Files for Mixed Shelf of Upto $400 Mln
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $9
Express News | Kezar Life Sciences Inc - Enters Into Amendment No. 1 to Rights Agreement
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
